Mosaic Variegated Aneuploidy Syndrome 3 C4539839
A rare genetic disorder causing cells to have variable numbers of chromosomes. Affected individuals may have developmental delay and increased risk of tumors. Surveillance and supportive management are essential components of care.
Key facts at a glance
- ICD-10
- Q89.9
- ICD-11
- LA00.0
- Body system
- congenital
- Severity
- severe
- Chronic
- true
Signs and symptoms
Common signs and symptoms that may indicate this condition.
Warning signs - seek immediate care
Seizures
Generalized symptoms
(congenital)Significant symptoms that substantially affect daily functioning.
Frequency: Common at all stages
Microcephaly
(neurological)Growth restriction
(growth)Cataracts
(sensory)Diagnosis and tests
How this condition is diagnosed and what test results mean.
Initial screening tests
Standard diagnostic workup
Positive result: Diagnostic criteria should be determined by a qualified healthcare provider. [Content pending medical review.]
Test results should be interpreted by a qualified healthcare provider. [Content pending medical review.]
Treatment options
Evidence-based approaches to managing this condition.
First-line treatments
Evidence-based pharmacological treatment
Active treatment with regular monitoring by a healthcare provider is recommended.
Neurological Surveillance Protocol
Regular neurological monitoring including head circumference measurement, developmental assessments, and neuroimaging as clinically indicated to detect microcephaly progression and structural brain abnormalities.
Seizure Control Therapy
Appropriate anticonvulsant therapy selected based on seizure semiology and electroencephalogram findings. Response to treatment should be monitored regularly with dose adjustments as needed.
Additional treatment options
Rehabilitative Therapy Services
Comprehensive physical and occupational therapy to address motor delays, improve functional abilities, and enhance quality of life. Therapy programs are individualized based on severity of motor impairment.
physical_therapyTumor Surveillance Program
Regular screening for malignancies associated with mosaic variegated aneuploidy, including regular physical examinations and age-appropriate cancer screenings. Early detection significantly improves outcomes.
monitoringNeuropsychological Support
Psychological support and cognitive assessment services to address intellectual disability, behavioral concerns, and emotional well-being. Individual and family counseling helps manage the challenges associated with the condition.
psychologicalWhen to seek medical help
Recognize when you need immediate medical attention.
See a doctor within 24 hours
Moderate to severe symptoms that may indicate worsening of this condition. Prompt medical evaluation is recommended.
Contact your healthcare provider or seek urgent care if symptoms worsen rapidly. Go to the emergency department for life-threatening symptoms.
Frequently asked questions
Common questions about this topic.
What is Mosaic Variegated Aneuploidy Syndrome 3 C4539839?
Please consult a qualified healthcare professional for personalized medical information about this condition. [Content pending medical review.]
generalMedication Comparisons
Compare medications used to treat Mosaic Variegated Aneuploidy Syndrome 3 C4539839. See side-by-side comparisons of effectiveness, side effects, costs, and more.
View Medication ComparisonsThis information is for educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment.
This content is for general informational and educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always seek the guidance of a qualified healthcare provider with any questions you have about a medical condition, and never disregard professional medical advice or delay seeking it because of something you read here.
If you think you may have a medical emergency, call your local emergency number or go to the nearest emergency department immediately.
Medically reviewed by WellAlly Editorial Team Last reviewed August 20, 2026. · Read our editorial policy